Department of Psychological Sciences, Swinburne University of Technology, Melbourne, Victoria, Australia.
School of Population Health, Faculty of Medicine and Health, University of New South Wales, Randwick, New South Wales, Australia.
Psychooncology. 2023 Apr;32(4):469-491. doi: 10.1002/pon.6094. Epub 2023 Jan 27.
Men diagnosed with localised prostate cancer (LPC) often face a difficult process deciding on a treatment choice that suits their personal preferences. This systematic review examines the impact of patient treatment decision-aids (DAs) on decisional outcomes and treatment choice for men diagnosed with LPC. Our secondary aim was to examine how DAs have been implemented into routine clinical practice.
A systematic search was conducted up to June 2022 using the following databases: Medline, Embase, PsycINFO, CINAHL, Cochrane, Scopus, and Web of Science. Articles were included if they evaluated the effectiveness of treatment DAs for LPC patients on various decisional outcomes and treatment choice. The Mixed-Method Appraisal Tool was used to assess methodological quality and risk of bias. Data on implementation outcomes were also extracted if reported.
Twenty-four articles were included for the analysis (seven non-randomised studies, 16 randomised control trials, and one qualitative study). Results showed DAs have the potential to improve patient knowledge but revealed no effects on decisional regret or preparedness in decision-making. Due to the variability in methodology among studies, results varied widely for treatment choice, decision-making involvement, decisional conflict, and treatment decision satisfaction. At least one implementation outcome was reported in 11 of the included studies, with the most commonly assessed outcomes being acceptability and appropriateness.
While DAs appear to improve knowledge, further qualitative evaluations and standardised assessments are needed to better understand men's experiences using DAs and to determine advantages and optimal ways to implement DAs into the treatment decision-making pathway.
被诊断为局限性前列腺癌(LPC)的男性在决定治疗选择时常常面临着一个艰难的过程,他们需要选择一个符合个人偏好的治疗方案。本系统评价研究了患者治疗决策辅助工具(DAs)对被诊断为 LPC 的男性的决策结果和治疗选择的影响。我们的次要目的是研究 DAs 是如何被纳入常规临床实践的。
我们对截至 2022 年 6 月的以下数据库进行了系统检索:Medline、Embase、PsycINFO、CINAHL、Cochrane、Scopus 和 Web of Science。如果文章评估了 LPC 患者的治疗 DAs 在各种决策结果和治疗选择方面的有效性,我们将其纳入研究。使用混合方法评估工具(Mixed-Method Appraisal Tool)评估方法学质量和偏倚风险。如果有报告实施结果,也会提取这些数据。
共纳入 24 篇文章进行分析(7 项非随机研究、16 项随机对照试验和 1 项定性研究)。结果表明,DAs 有可能提高患者的知识水平,但对决策后悔或决策准备感没有影响。由于研究方法的差异,治疗选择、决策参与度、决策冲突和治疗决策满意度等方面的结果差异很大。在纳入的 11 项研究中,至少有一项实施结果被报告,其中最常评估的结果是可接受性和适宜性。
虽然 DAs 似乎提高了知识水平,但需要进一步进行定性评估和标准化评估,以更好地了解男性使用 DAs 的体验,并确定将 DAs 纳入治疗决策途径的优势和最佳方法。